Medtronic Will Pay Edwards More Than $1 Billion To Settle TAVR Dispute
This article was originally published in The Gray Sheet
Executive Summary
A settlement between the two companies dismissing all pending patent litigation related to transcatheter valve replacement technologies ends years of legal wrangling and ensures that the U.S. TAVR market will have at least two competitors.